Stratagene is involved in settlement discussions with Applera and Third Wave Technologies in two separate cases, according to court documents filed over the past month.

Resolving the disputes could decrease Stratagene's legal expenses — around $5.3 million in 2005 — and erase concerns among potential partners that the firm's products may infringe other technologies. It could also provide a boost to Stratagene's sagging stock, which has hovered around its 52-week low for most of the past month.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.